Organon (OGN) Intangibles (2020 - 2026)
Organon (OGN) posted quarterly Intangibles of $1.1 billion for Q1 2026, up 2054.9% year-over-year from $51.0 million in Q1 2025, and down 2.74% on a QoQ basis from $1.1 billion in Q4 2025.
Organon (OGN) Intangibles (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Intangibles for 7 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles rose 2054.9% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 2054.9% YoY), while the FY2025 annual figure was $1.1 billion, down 20.08% from the prior year.
- Intangibles came in at $1.1 billion for Q1 2026 at Organon, down from $1.1 billion in the prior quarter.
- The five-year high for Intangibles was $24.5 billion in Q4 2023, with the low at $30.0 million in Q3 2025.
- Average Intangibles over 5 years is $2.1 billion, with a median of $649.0 million recorded in 2022.
- Across the five-year window, Intangibles soared 3678.27% in 2023 and sank 94.23% in 2024, its largest moves.
- Year by year, Intangibles stood at $649.0 million in 2022, then jumped by 3678.27% to $24.5 billion in 2023, then tumbled by 94.23% to $1.4 billion in 2024, then decreased by 20.08% to $1.1 billion in 2025, then decreased by 2.74% to $1.1 billion in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $1.1 billion, $1.1 billion, and $30.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.37 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 49.06 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 50.87 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 36.91 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 11.30 Bn |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | 1.10 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.10 Bn |
| Dec 31, 2025 | 1.13 Bn |
| Sep 30, 2025 | 30.00 Mn |
| Jun 30, 2025 | 1.36 Bn |
| Mar 31, 2025 | 51.00 Mn |
| Dec 31, 2024 | 1.41 Bn |
| Sep 30, 2024 | 113.00 Mn |
| Jun 30, 2024 | 684.00 Mn |
| Mar 31, 2024 | 220.00 Mn |
| Dec 31, 2023 | 24.52 Bn |
| Sep 30, 2023 | 561.00 Mn |
| Jun 30, 2023 | 592.00 Mn |
| Mar 31, 2023 | 621.00 Mn |
| Dec 31, 2022 | 649.00 Mn |
| Sep 30, 2022 | 670.00 Mn |
| Jun 30, 2022 | 638.00 Mn |
| Mar 31, 2022 | 665.00 Mn |
| Dec 31, 2021 | 651.00 Mn |
| Sep 30, 2021 | 683.00 Mn |
| Jun 30, 2021 | 711.00 Mn |